Picture Swiss Biotech Association LSE Global Village 2025 Basel 650x100px

Document › Details

BiondVax Pharmaceuticals Ltd.. (1/28/21). "Press Release: BiondVax Announces Third Quarter 2020 Financial Results & Business Update". Jerusalem.

	Organisation	BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)
	Today	Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI)
	Group	Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI)
	Organisation 2	European Investment Bank (EIB)
	Group	EU (govt)
	Product	M-001 universal flu vaccine (BiondVax)
	Product 2	anti-infective drug
	Person	Reichman, Amir (BiondVax 202103– CEO before GSK Vaccines + Novartis Vaccines + NeuroDerm)
	Person 2	Phillipson, Joshua E. (BiondVax 201707 Business Development Manager)

Original document
accessed by [iito] on 2021-01-30

Record changed: 2024-08-24

Picture Berlin Partner Top News Robotics Network Berlin-Brandenburg 650x200px

More documents for Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI)

[1] Scinai Immunotherapeutics Ltd.. (2/13/24). "Press Release: Scinai Welcomes Liat Halpert as Head of Business Development and Sales". Jerusalem....
[2] Scinai Immunotherapeutics Ltd.. (9/19/23). "Press Release: Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering". Jerusalem....
[3] Scinai Immunotherapeutics Ltd.. (9/15/23). "Press Release: Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering". Jerusalem....
[4] Scinai Immunotherapeutics Ltd.. (9/11/23). "Press Release: Scinai Immunotherapeutics Ltd. to Participate This Week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston". Jerusalem....
[5] Scinai Immunotherapeutics Ltd.. (9/6/23). "Press Release: BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics". Jerusalem....
[6] BiondVax Pharmaceuticals Ltd.. (8/11/23). "Press Release: BiondVax Reports Second Quarter Financial Results and Provides Business Update". Jerusalem....
[7] BiondVax Pharmaceuticals Ltd.. (8/1/23). "Press Release: Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules". Jerusalem....
[8] BiondVax Pharmaceuticals Ltd.. (6/5/23). "Press Release: BiondVax Signs Exclusive License Agreement for Development and Commercialization of a Novel anti-IL-17 Antibody". Jerusalem....
[9] BiondVax Pharmaceuticals Ltd.. (1/29/21). "Press Release: BiondVax Announces Pricing of $12.1 Million Follow-on Underwritten Offering of American Depositary Shares". Jerusalem....
[10] BiondVax Pharmaceuticals Ltd.. (1/28/21). "Press Release: BiondVax Announces Launch of Proposed Underwritten Follow-on Offering of American Depositary Shares". Jerusalem....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]